Setterwalls advises Guard Therapeutics AB in connection with a rights issue

Setterwalls advises Guard Therapeutics International AB (publ) (“Guard Therapeutics”) in connection with a rights issue of shares.

Guard Therapeutics is a Swedish biotechnology company developing innovative drugs in areas with significant medical needs, with a particular focus on kidney disease. The company’s primary drug candidate RMC-035 is in clinical phase and is being developed as a kidney-protective treatment in open-heart surgery and kidney transplantation. Guard Therapeutics is listed on Nasdaq First North Growth Market.

Through the rights issue, Guard Therapeutics will receive issue proceeds of approximately SEK 120 million before issue costs.